Genetic analysis of the multidrug transporter
- PMID: 8825488
- DOI: 10.1146/annurev.ge.29.120195.003135
Genetic analysis of the multidrug transporter
Abstract
The analysis of how human cancers evade chemotherapy has revealed a rich variety of cell-based genetic changes resulting in drug resistance. One of the best studied of these genetic alterations is increased expression of an ATP-dependent plasma membrane transport system, known as P-glycoprotein, or the multidrug transporter. This transporter actively effluxes a large number of natural product, hydrophobic, cytotoxic drugs, including many important anticancer agents. This review focuses on the genetic and molecular genetic analysis of the human multidrug transporter, including structure-function analysis, pre- and posttranslational regulation of expression, the role of gene amplification in increased expression, and the properties of transgenic and "knock-out" mice. One important feature of the MDR gene is its potential for the development of new selectable vectors for human gene therapy.
Similar articles
-
Regulation of the multidrug resistance (MDR1) gene expression.In Vivo. 1994 Nov-Dec;8(5):835-41. In Vivo. 1994. PMID: 7727733 Review.
-
Differential effects of P-glycoprotein inhibitors on NIH3T3 cells transfected with wild-type (G185) or mutant (V185) multidrug transporters.Cancer Res. 1995 Mar 1;55(5):1086-91. Cancer Res. 1995. PMID: 7866993
-
Multidrug resistance: molecular and clinical aspects.Cytokines Cell Mol Ther. 1997 Jun;3(2):91-9. Cytokines Cell Mol Ther. 1997. PMID: 9287248 Review.
-
Biochemical, cellular, and pharmacological aspects of the multidrug transporter.Annu Rev Pharmacol Toxicol. 1999;39:361-98. doi: 10.1146/annurev.pharmtox.39.1.361. Annu Rev Pharmacol Toxicol. 1999. PMID: 10331089 Review.
-
Molecular mechanisms of multidrug resistance in cancer chemotherapy.Pathol Res Pract. 1996 Jul;192(7):768-80. doi: 10.1016/S0344-0338(96)80099-9. Pathol Res Pract. 1996. PMID: 8880878 Review.
Cited by
-
Blood brain barrier: a challenge for effectual therapy of brain tumors.Biomed Res Int. 2015;2015:320941. doi: 10.1155/2015/320941. Epub 2015 Mar 19. Biomed Res Int. 2015. PMID: 25866775 Free PMC article. Review.
-
Targeting transporters: promoting blood-brain barrier repair in response to oxidative stress injury.Brain Res. 2015 Oct 14;1623:39-52. doi: 10.1016/j.brainres.2015.03.018. Epub 2015 Mar 18. Brain Res. 2015. PMID: 25796436 Free PMC article. Review.
-
Clinically-Relevant ABC Transporter for Anti-Cancer Drug Resistance.Front Pharmacol. 2021 Apr 19;12:648407. doi: 10.3389/fphar.2021.648407. eCollection 2021. Front Pharmacol. 2021. PMID: 33953682 Free PMC article. Review.
-
Role of Cys-603 in dimer/oligomer formation of the breast cancer resistance protein BCRP/ABCG2.Cancer Sci. 2005 Dec;96(12):866-72. doi: 10.1111/j.1349-7006.2005.00126.x. Cancer Sci. 2005. PMID: 16367905 Free PMC article.
-
Inhibitory effect of the reversal agents V-104, GF120918 and Pluronic L61 on MDR1 Pgp-, MRP1- and MRP2-mediated transport.Br J Cancer. 2000 Aug;83(3):366-74. doi: 10.1054/bjoc.2000.1260. Br J Cancer. 2000. PMID: 10917553 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources